Misplaced Pages

Indium (In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer. Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).

Early trials with yttrium (Y) capromab pendetide were also conducted.

References

1. ^ Manyak MJ (February 2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–81. doi:10.1586/14737140.8.2.175. PMID 18279057. S2CID 30587577.
2. WHO Drug Information
3. Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (April 1999). "A phase II study of yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99–111. doi:10.1089/cbr.1999.14.99. PMID 10850293.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This nuclear medicine article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Radiopharmaceuticals
• Antibody-drug conjugates
• Indium compounds
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs
• Nuclear medicine stubs